ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Ozempic, Wegovy and other weight loss drugs present holiday challenges

Holiday prep may include forgoing doses for some people taking medications popularly used to facilitate weight loss. Those who do that need to be careful when resuming them, an expert said.

Celebrating the winter holidays for many means buying presents, arranging travel and planning hefty menus for meals with loved ones. However, this year those preparations may include skipping medications popularly used to facilitate weight loss. 

Reasons ranging from wanting to consume more holiday food without post-meal discomfort to aiming to save money have prompted some to look to hold off on doses in the lead-up to the festivities, according to Good Morning America and other media reports. 

Still, individuals contemplating skipping their weight loss drugs need to be careful when resuming them afterwards, an expert told FOX Business.

Common types of drugs used for weight loss include Ozempic, Wegovy and Mounjaro. The last contains tirzepatide, while the other two are semaglutide. 

FDA APPROVES ELI LILLY'S TIRZEPATIDE FOR WEIGHT LOSS

Endobariatric physician and True You Weight Loss Associate Research Director Dr. Dan Maselli told FOX Business that such reasons are "totally understandable." Some of his patients have wanted to interrupt their dosage schedule to avoid receiving stigma-driven judgment from loved ones who didn’t know they were taking such medication, he added.

Individuals are not "going to harm themselves in the immediate future by stopping the medication" they use for weight loss, Maselli said. While skipping may lead to feelings of hunger, drugs like Ozempic and Mounjaro do not bring on a withdrawal phenomenon, he noted.

It is the resumption of the medication where people need to be careful, according to Maselli.

"These medications are really meant to be taken long-term and consistently, and one of the issues that can arise if we miss a dose, or really if we miss two to three doses, is that our body can lose how well acclimated it has become to those medications, in particular to the gastrointestinal side effects of those medications," Maselli said. "It may be unwise and, in extreme circumstances, unsafe to start the medication back at the dose you were at."

When using Ozempic, Mounjaro and other similar drugs for weight loss, doctors and patients have to start at a low dosage and slowly increase it over time, he explained. That process can take 20 weeks.

PATIENTS STOP WEGOVY, OTHER WEIGHT-LOSS RELATED DRUGS SHORTLY AFTER STARTING, DOCTORS SAY

"So if you were at that maximum dose – or even above like the first two doses of this medication – and you stop this medication for two or three weeks, and then you try to start back on that same dose, you can make yourself really uncomfortable," he said.

Nausea, vomiting, diarrhea, constipation, cramping and heartburn are among the symptoms a person could experience.

Maselli said that people who have missed or skipped doses should get in touch with their prescribing doctor instead of just starting back up again, because their doctor may need to lower their dose. In some cases, they could need to start from square one, depending on how long it has been.

People deciding to temporarily stop taking the drugs during the holidays comes after more and more people have looked to Ozempic, Wegovy and Mounjaro for weight-loss help. 

WEIGHTWATCHERS BETS ON WEIGHT-LOSS DRUGS WITH LAUNCH OF NEW PROGRAM

Novo Nordisk, which produces Ozempic and Wegovy, has seen quite a boost amid the phenomenon, with its stock price having climbed nearly 51% since the start of 2023. Shares of the company behind Mounjaro, Eli Lilly, have gone up over 56%. 

The S&P 500, meanwhile, has posted a nearly 25% increase this year.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.